Metallocene Compounds for Drug-Resistant Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges with drug-resistant tumors, necessitating the development of new therapeutic agents to improve survival rates.
Innovation Solution
The use of metallocene compounds, specifically those with formulas CPH-1 to CPH-15 and their pharmaceutically acceptable salts, for treating cancer by inhibiting or reducing tumor growth, either alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new therapeutic agents are developed to overcome drug-resistant tumors, then cancer treatment effectiveness is improved, but treatment complexity and development cost increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of metallocene compounds through various substitutions (aryl, alkyl, heteroatom groups) and coordination spheres to create a series of derivatives with different biological activities and resistance profiles, thereby improving treatment effectiveness while maintaining a manageable structural framework
Solution Approach 2:
The patent employs composite materials by combining metallocene core structures with various ligand systems and substituent groups to create hybrid compounds that integrate multiple functional properties, achieving enhanced anti-cancer activity against resistant tumors while utilizing established synthetic methodologies
2Object-affected harmful factors
If metallocene compounds are used to inhibit tumor growth, then cancer cell viability is reduced, but potential toxicity to healthy cells may increase
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the metallocene scaffold, creating compounds with localized electronic and steric properties that enhance selective binding to cancer cell targets while minimizing off-target effects on healthy cells
Solution Approach 2:
The patent uses copying by creating multiple analogs and derivatives that replicate the core anti-cancer mechanism of the parent metallocene compound while incorporating modifications to improve selectivity and reduce systemic toxicity, allowing identification of optimal structures through structure-activity relationship studies
Data Source
AI summary
Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided.